THROBEX 15MG is brand name of Rivaroxaban 15 mg indicated for the prophylaxis and treatment of Deep Vein Thrombosis and Venous Thromboembolism and also indicated in Nonvalvular Atrial Fibrillation and reduction in the risk of Major Adverse Cardiovascular Events (MACE). Throbex is an oral, direct factor Xa inhibitor that selectively blocks the active site of Xa and does not require a co-factor. Rivaroxaban lowers the risk of blood clots by inhibiting both free and prothrombinase-bound or clot-bound factor Xa as well as downstream platelet activation.
Antithrombotic Agents, Direct Factor Xa Inhibitors.
Dose and Direction of Use
Take this medication by mouth with or without food as directed by your doctor, usually twice daily at the same time. Take a low-dose aspirin (usually 75-100 milligrams) once a day as prescribed by your doctor. If you are unable to swallow whole tablets, you may crush the tablet and mix it with applesauce. Eat the entire mixture right away. Do not prepare a supply for future use. Follow your doctor's directions carefully.
Mode of Action
Rivaroxaban competitively inhibits free and clot bound factor Xa. Factor Xa is needed to activate prothrombin (factor II) to thrombin (factor IIa). Thrombin is a serine protease that is required to activate both platelets and catalyzes the conversion of fibrinogen to fibrin, which is the loose meshwork that completes the clotting process. Since one molecule of factor Xa can generate more than 1000 molecules of thrombin, selective inhibitors of factor Xa are profoundly useful in terminating the amplification of thrombin generation. The action of rivaroxaban is irreversible.
- RIVAROX is co-administered with acetylsalicylic acid (ASA) alone or with ASA plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (ACS) with elevated cardiac biomarkers.
- RIVAROX, co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) at high risk of ischemic events.
- Prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery.
- Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.
Don't use this medicine if you have:
- Hypersensitivity to the active substance or to any of the excipients.
- Active clinically significant bleeding
Precautions and Warning
- As with other anticoagulants, patients taking RIVAROX are to be carefully observed for signs of bleeding. It is recommended to be used with caution in conditions with increased risk of bleeding. RIVAROX administration should be discontinued if severe bleeding occurs.
- There might be risk of stomach bleeding which may also be supported by alcohol. So, alcoholic drinks should be limited.
- Tell your doctor about medical history as such liver problem, kidney problem, bleeding disorder, injuries.
- Tell your doctor if you are pregnant or planning to get pregnant. This medication is taken during pregnancy only when needed after discussing the risk and benefit factor with doctor.
- This medication passes through breast milk. Consult your doctor before breast-feeding.
- In the clinical studies mucosal bleedings (i.e. epistaxis, gingival, gastrointestinal, genito urinary including abnormal vaginal or increased menstrual bleeding) and anemia were seen more frequently during long term rivaroxaban treatment on top of single or dual anti-platelet therapy. Thus, in addition to adequate clinical surveillance, laboratory testing of hemoglobin/hematocrit could be of value to detect occult bleeding and quantify the clinical relevance of overt bleeding, as judged to be appropriate.
- Any unexplained fall in hemoglobin or blood pressure should lead to a search for a bleeding site.